CID13 Antibody

Shipped with Ice Packs
In Stock
Cat. No.
BT1213247
Synonyms
CID13 antibody; At5g24440 antibody; T31K7.2Polyadenylate-binding protein-interacting protein 13 antibody; PABP-interacting protein 13 antibody; Poly(A)-binding protein-interacting protein 13 antibody; PAM2-containing protein CID13 antibody; Protein CTC-INTERACTING DOMAIN 13 antibody
Quick Inquiry

Description

Research and Diagnostic Applications of CD13 Antibodies

CD13 antibodies are widely utilized in flow cytometry, immunohistochemistry, and functional studies:

CloneIsotypeApplicationsSpecificitySource
WM15 (WM-15)IgG1Flow cytometry, microscopyDetects extracellular epitope on CD13Thermo Fisher
38C12IgG1IHC (paraffin, frozen), myeloid leukemiaCytoplasmic/membranous CD13Bio SB
L138 (Leu-M7)IgG1Flow cytometry, phagocytosis studiesGlycosylated 150 kDa CD13BD Biosciences

Notable Findings:

  • WM15 clone shows high specificity for myeloid cells and epithelial tissues, making it suitable for distinguishing CD13⁺ tumors .

  • Clone 38C12 aids in diagnosing acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in blast crisis .

Therapeutic Potential of CD13-Targeting Antibodies

CD13 is an emerging target for antibody-drug conjugates (ADCs) and anti-inflammatory therapies:

Antibody-Drug Conjugates (ADCs)

  • MI130110: Conjugates anti-CD13 monoclonal antibody (TEA1/8) with cytotoxic compound PM050489. Demonstrates:

    • In Vitro Efficacy: IC₅₀ of 0.2–0.4 nM in CD13⁺ HT1080 fibrosarcoma cells .

    • In Vivo Selectivity: Complete remission in 60% of HT1080 xenograft models; no activity in CD13⁻ myeloma models .

    • Mechanism: Induces G2/M arrest and mitotic catastrophe via microtubule disruption .

Inflammatory Disease Targeting

  • CD13 Inhibitors (e.g., actinonin, probestin):

    • Reduce IL-1β, IL-17, and TNF-α in rheumatoid arthritis models .

    • Suppress monocyte infiltration and angiogenesis in murine colitis .

Diagnostic Use Cases

  • Leukemia Subtyping: CD13 expression distinguishes AML (80–90% positivity) from lymphoid leukemias (<10%) .

  • Tumor Microenvironment Analysis: CD13⁺ fibroblasts correlate with poor prognosis in colorectal cancer .

Challenges and Future Directions

  • Therapeutic Limitations: Off-target effects of CD13 inhibitors in non-immune tissues (e.g., renal tubules) .

  • Research Gaps: Role of soluble CD13 (sCD13) in cytokine signaling remains poorly characterized .

  • Innovative Approaches: Bispecific antibodies targeting CD13 and checkpoint inhibitors (e.g., PD-1) are under preclinical evaluation .

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
14-16 week lead time (made-to-order)
Synonyms
CID13 antibody; At5g24440 antibody; T31K7.2Polyadenylate-binding protein-interacting protein 13 antibody; PABP-interacting protein 13 antibody; Poly(A)-binding protein-interacting protein 13 antibody; PAM2-containing protein CID13 antibody; Protein CTC-INTERACTING DOMAIN 13 antibody
Target Names
CID13
Uniprot No.
Q9FGE6

Q&A

CD13 Antibody Research FAQs
Assuming "CID13" refers to CD13 (Aminopeptidase N) based on contextual analysis of provided sources. Critical research considerations below address both fundamental and advanced study design challenges.

Advanced Experimental Design

How to resolve contradictory data on CD13 internalization kinetics across studies?

  • Conflict: Reported internalization rates vary from 15–90 minutes post-antibody binding .

  • Solution: Standardize using:

    • Temporal sampling: Quantify antibody remaining on HT1080 cell surfaces at 5/15/30/60 min via pH-sensitive fluorescent tags.

    • Control: Compare TEA1/8-conjugated antibodies (MI130110 ADC) vs. non-conjugated forms to rule out payload interference .

What in vivo models best predict therapeutic antibody efficacy against CD13+ tumors?

  • Optimal model: Fibrosarcoma xenografts (HT1080 lineage) showing:

    • 100% tumor regression at 3 mg/kg MI130110 ADC

    • Mitotic catastrophe histopathology (multipolar spindles, metaphase arrest) matching in vitro MOA

  • Avoid: Myeloma models lacking CD13 expression (e.g., RPMI-8226) due to 0% response rates .

Technical Validation Challenges

How to address species cross-reactivity gaps in preclinical antibody development?

  • Case study: Human IL-13 antibody 731 exhibited 400-fold lower affinity for NHP targets .

  • Mitigation strategy:

    • RSS-directed CDR mutagenesis to diversify paratopes

    • Mammalian display screening for cross-species affinity (e.g., achieved 34 fM KD for human IL-13 vs. 142 fM for NHP variant)

What controls are essential when quantifying CD13-mediated cytotoxicity?

  • Required controls:

    • CD13-knockout isogenic cell lines (CRISPR-generated)

    • Competitive inhibition with soluble CD13 extracellular domain

    • Parallel assessment of apoptosis markers (caspase-3/7) vs. mitotic arrest (pH3 Ser10 phosphorylation)

Mechanistic Insight Generation

How to differentiate direct CD13 signaling effects from epitope-masking artifacts?

  • Experimental framework:

    • Compare WT vs. CD13-KO cells transfected with:

      • Full-length CD13

      • Signaling-deficient mutants (e.g., ΔCytoplasmic tail)

    • Measure downstream pathways (NF-κB, MAPK) via phospho-flow cytometry

  • Key finding: Anti-CD13 antibodies induce IL-8 secretion only in full-length CD13 transfectants (p<0.001 vs. mutants)

Methodological Note: Always verify antibody lots via:

  • Binding kinetics: SPR/BLI confirming ≤10% KD variation from reference

  • Functional equivalence: ≥80% inhibition in standardized internalization assay vs. historical data

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2025 TheBiotek. All Rights Reserved.